Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
University of Dundee · MRC Centre for Regenerative Medicine · +7 more institutions
Abstract
Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis and stimulate liver regeneration. In a multicenter, open-label, parallel-group, phase 2 randomized controlled trial ( ISRCTN10368050 ) in n = 51 adult patients with compensated cirrhosis and Model for End-Stage Liver Disease (MELD) score ≥10 and ≤17, we evaluated the efficacy of autologous monocyte-derived macrophage therapy (n = 27) compared to standard medical care (n = 24). The primary endpoint was the difference in baseline to day 90 change in MELD score (ΔMELD)…
Citation impact
- FWCI
- 45.04
- Percentile
- 100%
- References
- 53
Authors
22- PBPaul BrennanCorresponding
University of Dundee, MRC Centre for Regenerative Medicine, University of Edinburgh
- MTMark T. Macmillan
MRC Centre for Regenerative Medicine, University of Edinburgh
- TMThomas Manship
Edinburgh Royal Infirmary
- FMFrancesca Moroni
Aberdeen Royal Infirmary
- AGAlison Glover
Scottish National Blood Transfusion Service
Topics & keywords
- Medicine
- Cirrhosis
- Clinical endpoint
- Internal medicine
- Adverse effect
- Gastroenterology
- Liver transplantation
- Randomized controlled trial
- Good health and well-being